These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 33524539)

  • 1. Anticoagulant or antiplatelet use and severe COVID-19 disease: A propensity score-matched territory-wide study.
    Zhou J; Lee S; Guo CL; Chang C; Liu T; Leung KSK; Wai AKC; Cheung BMY; Tse G; Zhang Q
    Pharmacol Res; 2021 Mar; 165():105473. PubMed ID: 33524539
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of current antithrombotic therapy on mortality in nursing home residents with COVID-19: a multicentre retrospective cohort study.
    Boutkourt F; van Haaps T; Brüggemann R; Bhoelan S; Ten Cate H; Kruip MJHA; Spaetgens B; van Es N; Roest T; Joling KJ; Meijer K; Hugtenburg J
    Age Ageing; 2024 May; 53(5):. PubMed ID: 38748450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antithrombotic drug (thrombolytic drug, anticoagulant, antiplatelet drug)].
    Matsuda T
    Nihon Rinsho; 1993 Nov; 51 Suppl():179-85. PubMed ID: 8283663
    [No Abstract]   [Full Text] [Related]  

  • 4. Antiplatelet, anticoagulant and fibrinolytic agents in acute ischaemic stroke and TIA.
    Sandercock P; Lindley R; Wardlaw J
    Br J Hosp Med; 1992 May 20-Jun 2; 47(10):731-7. PubMed ID: 1606457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic Medication and the Risk of Vitreous Hemorrhage in Atrial Fibrillation: Korean National Health Insurance Service National Cohort.
    Kim KE; Yang PS; Jang E; Kim S; Joung B
    Yonsei Med J; 2019 Jan; 60(1):65-72. PubMed ID: 30554492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study.
    Zhou J; Wang X; Lee S; Wu WKK; Cheung BMY; Zhang Q; Tse G
    Gut; 2021 Oct; 70(10):2012-2013. PubMed ID: 33277346
    [No Abstract]   [Full Text] [Related]  

  • 7. Antiplatelet Therapy in Patients With COVID-19-More Is Less?
    Spaetgens B; Nagy M; Ten Cate H
    JAMA; 2022 Jan; 327(3):223-224. PubMed ID: 35040901
    [No Abstract]   [Full Text] [Related]  

  • 8. Hypercoagulability in dogs: treatment.
    Kitrell D; Berkwitt L
    Compend Contin Educ Vet; 2012 May; 34(5):E3. PubMed ID: 22581723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [An antithrombotic therapy from the viewpoint of hematology].
    Asakura H
    Brain Nerve; 2015 Jan; 67(1):83-91. PubMed ID: 25585437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antiplatelet and anticoagulant therapy for stroke prevention in patients with non-valvular atrial fibrillation: evidence based strategies and new developments].
    Gersh BJ; Freedman JE; Granger CB
    Rev Esp Cardiol; 2011 Apr; 64(4):260-8. PubMed ID: 21411211
    [No Abstract]   [Full Text] [Related]  

  • 11. Association of chronic anticoagulant and antiplatelet use on disease severity in SARS-COV-2 infected patients.
    Ho G; Dusendang JR; Schmittdiel J; Kavecansky J; Tavakoli J; Pai A
    J Thromb Thrombolysis; 2021 Aug; 52(2):476-481. PubMed ID: 33527183
    [No Abstract]   [Full Text] [Related]  

  • 12. The use of antiplatelet agents for arterial thromboprophylaxis in COVID-19.
    Kow CS; Hasan SS
    Rev Esp Cardiol (Engl Ed); 2021 Jan; 74(1):114-115. PubMed ID: 32933883
    [No Abstract]   [Full Text] [Related]  

  • 13. Antithrombotic therapy in peripheral artery disease--antiplatelet therapy, anticoagulants, both or none.
    Tangelder MJ; van Hattum ES
    Thromb Haemost; 2010 Aug; 104(2):196-9. PubMed ID: 20508897
    [No Abstract]   [Full Text] [Related]  

  • 14. Emergency Reversal Strategies for Anticoagulation and Platelet Disorders.
    Levi M
    Front Neurol Neurosci; 2015; 37():51-61. PubMed ID: 26587647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges in managing venous thromboembolism and acute coronary syndrome: case studies of the use of antithrombotic and antiplatelet therapies. Introduction.
    Haines ST
    Am J Health Syst Pharm; 2008 Aug; 65(15 Suppl 7):S3-4. PubMed ID: 18653823
    [No Abstract]   [Full Text] [Related]  

  • 16. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1.
    Gorin L; Fauchier L; Nonin E; de Labriolle A; Haguenoer K; Cosnay P; Babuty D; Charbonnier B
    Thromb Haemost; 2010 Apr; 103(4):833-40. PubMed ID: 20135077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Previous Antithrombotic Therapy, Particularly Anticoagulant, Is Associated with Unfavorable Outcomes in Patients with Primary Spontaneous Intracerebral Hemorrhage Receiving Craniotomy: A Nationwide Population-Based Cohort Study.
    Liu ZH; Chen NY; Tu PH; Yip PK; Wang YC; Chen CC; Chuang CC; Liu CH; Hsu PW; Lin YS
    World Neurosurg; 2019 Aug; 128():e59-e73. PubMed ID: 30954751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome].
    Tubaro M; Falaschi G; Colivicchi F
    G Ital Cardiol (Rome); 2018 Oct; 19(10):552-562. PubMed ID: 30281043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation.
    Dzeshka MS; Lip GY
    Heart Fail Clin; 2016 Apr; 12(2):257-71. PubMed ID: 26968670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study.
    Helms J; Tacquard C; Severac F; Leonard-Lorant I; Ohana M; Delabranche X; Merdji H; Clere-Jehl R; Schenck M; Fagot Gandet F; Fafi-Kremer S; Castelain V; Schneider F; Grunebaum L; Anglés-Cano E; Sattler L; Mertes PM; Meziani F;
    Intensive Care Med; 2020 Jun; 46(6):1089-1098. PubMed ID: 32367170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.